TAF1L — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL1906368	1.00	1/20
SCHEMBL1907498	1.00	1/20
SCHEMBL221384	0.85	1/20
SCHEMBL223735	0.85	1/20
SCHEMBL1902031	0.83	1/20
SCHEMBL8225867	0.82	1/20
SCHEMBL1903230	0.78	1/20
SCHEMBL1904822	0.78	1/20
SCHEMBL1905787	0.78	1/20
SCHEMBL5836486	0.77	1/20
SCHEMBL5836491	0.77	1/20
SCHEMBL5836493	0.77	1/20
SCHEMBL1902624	0.77	1/20
SCHEMBL2741210	0.76	1/20
SCHEMBL5837528	0.75	1/20
SCHEMBL5837533	0.75	1/20
SCHEMBL223142	0.73	1/20
SCHEMBL224646	0.73	1/20
SCHEMBL223130	0.72	1/20
SCHEMBL223651	0.72	1/20

Clinical trials — most relevant to TAF1L by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS	PHASE2	COMPLETED
A Study of Bezafibrate in Mitochondrial Myopathy	PHASE2	COMPLETED
Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma	PHASE1/PHASE2	COMPLETED
A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL	PHASE1/PHASE2	RECRUITING
Vorinostat in Children	PHASE1/PHASE2	COMPLETED
Evaluation of the Safety and the Tolerability of a Combination of Two HIV Inducers in Patients With Undetectable Viral Load	PHASE1	COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome	PHASE1	COMPLETED
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck	PHASE1	COMPLETED
Imetelstat for Children With Refractory or Recurrent Solid Tumors and Lymphoma	PHASE1	WITHDRAWN
Safety, Tolerability and Pharmacokinetics of Benfo-Oxythiamine (B-OT) in Healthy Volunteers	PHASE1	COMPLETED
Autophagy in Systemic Lupus Erythematosus	nan	UNKNOWN
Spironolactone and XPB-1 Integrity in the TFIIH Complex	nan	ENROLLING_BY_INVITATION
Endolymphatic Sac Tumors in a Population of Patients With Von Hippel-Lindau Disease:The Natural History and Pathobiology, and a Prospective Non-Randomized Clinical Trial of Hearing Preservation Surgery in Patients With Early Stage Endolymphatic Sac Tumors	nan	COMPLETED
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics	nan	UNKNOWN
Amyotrophic Lateral Sclerosis (ALS) Families Project	nan	RECRUITING
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia	nan	UNKNOWN
Identification of New FTLD Genes	nan	UNKNOWN
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED
Telomere and Telomerase	nan	WITHDRAWN
Diagnosis of RSTS: Identification of the Acetylation Profiles as Epigenetic Markers for Assessing Causality of CREBBP and EP300 Variants.	nan	UNKNOWN
Role of SF3B1 Mutation in Assessment of Acute and Chronic Lymphatic Leukemia	nan	NOT_YET_RECRUITING
Assessment Of Long Noncoding RNA CCAT1 In Colorectal Cancer Patients	nan	UNKNOWN
Abnormalities in the Effects of Insulin and Exercise on Glucose- and Lipid Metabolism in Obesity and Type 2 Diabetes	nan	COMPLETED
Biological Aging Hallmarks-Guided Integrative TCM and Conventional Medicine in Post-Treatment Unexplained Female Infertility	nan	RECRUITING
Novel Biomarkers in the Neoplastic Progression of Barrett's Esophagus	nan	ACTIVE_NOT_RECRUITING
Gene Expression Variation and Implant Wound Healing Among Smokers and Diabetics	nan	COMPLETED
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients	nan	RECRUITING
Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients	nan	ACTIVE_NOT_RECRUITING
Immune Interactions in Severe Asthma	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a TAF1L binder may also engage these)

Protein	Name	Similarity
Q80UV9	—	1.000	Q80UV9 →
TAF1	Transcription initiation factor TFIID subunit 1	0.996	landscape →
Q60544	—	0.990	Q60544 →
Q8K2L8	—	0.981	Q8K2L8 →
P49140	—	0.980	P49140 →
KAT2B	Histone acetyltransferase KAT2B	0.978	landscape →
Q3UJB0	—	0.978	Q3UJB0 →
A0JMR6	—	0.977	A0JMR6 →
Q8R2T8	—	0.977	Q8R2T8 →
Q80TJ7	—	0.977	Q80TJ7 →
Q3UQU0	—	0.976	Q3UQU0 →
F4HRV8	—	0.976	F4HRV8 →
Q28C33	—	0.976	Q28C33 →
Q53F19	—	0.976	Q53F19 →
Q02225	—	0.976	Q02225 →
P51123	—	0.975	P51123 →
Q4VGL6	—	0.975	Q4VGL6 →
Q5XJV7	—	0.975	Q5XJV7 →
O54828	—	0.975	O54828 →
SF3B2	Splicing factor 3B subunit 2	0.975	landscape →
E1BTG2	—	0.975	E1BTG2 →
Q1LUC3	—	0.975	Q1LUC3 →
SMARCC2	SWI/SNF complex subunit SMARCC2	0.975	landscape →
Q8QG78	—	0.975	Q8QG78 →
Q9UPY6	—	0.975	Q9UPY6 →
Q5R6Y9	—	0.975	Q5R6Y9 →
A7MBP4	—	0.974	A7MBP4 →
Q92558	—	0.974	Q92558 →
Q66IV1	—	0.974	Q66IV1 →
Q5NVG8	—	0.974	Q5NVG8 →